Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2009 Jun 1.

Published in final edited form as: Mol Cancer Ther. 2008 Jun;7(6):1506–1513. doi: 10.1158/1535-7163.MCT-07-2334

In mutant cells where HIF-1αis non- functional, CCI-779 does not increase 2-DG toxicity under hypoxic conditions. (A, B) Cytotoxicity assays in HEPA (HIF+) and C4 (HIF−) cells after exposure to various doses of 2-DG and 0.1μg/ml of CCI-779 under hypoxic conditions for 48h. Note the increase in cell death after treatment with 2-DG in combination with CCI-779 in the (A) HEPA cell line that expresses functional HIF but not in the (P<0.02) (B) C4 HIF-deficient mutant cell line (P<0.05). (C) Cytotoxicity assays in 4 SCLC vs. 2 NSCLC lines. Note that in NSCLC cells which do not express HIF under hypoxia, co-treatment with CCI-779 and 2-DG results in decreased toxicity. Each data point is the average of triplicate samples with S.D. *P=0.001,**P=0.002

In mutant cells where HIF-1αis non- functional, CCI-779 does not increase 2-DG toxicity under hypoxic conditions. (A, B) Cytotoxicity assays in HEPA (HIF+) and C4 (HIF−) cells after exposure to various doses of 2-DG and 0.1μg/ml of CCI-779 under hypoxic conditions for 48h. Note the increase in cell death after treatment with 2-DG in combination with CCI-779 in the (A) HEPA cell line that expresses functional HIF but not in the (P<0.02) (B) C4 HIF-deficient mutant cell line (P<0.05). (C) Cytotoxicity assays in 4 SCLC vs. 2 NSCLC lines. Note that in NSCLC cells which do not express HIF under hypoxia, co-treatment with CCI-779 and 2-DG results in decreased toxicity. Each data point is the average of triplicate samples with S.D. *P=0.001,**P=0.002